Global Corporate Venturing ran a short survey of corporate venture capital investors on the impact of the Covid-19 pandemic in April.

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.

Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Cullinan Oncology contributed to a series A round that funded the launch of a cancer drug-focused joint venture with PDI Therapeutics.

Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.

Tencent-backed telemedicine service Miaoshou Doctor pulled in $84.5m that will support the strengthening of its health insurance provision.

Genomic heart disease drug developer Verve Therapeutics secured funding in a round led by GV, which also led its series A last year.

GenScript Biotech's spinoff Legend Biotech, which counts Eli Lilly and Johnson & Johnson as backers, floated in the US.

The emergency response software provider, which counts AAA, CSAA, Microsoft and Motorola Solutions as investors, lifted its total funding to $107m.